Dra. Mar Tormo Díaz

Investigador Principal
Grupo de investigación en neoplasias de línea mieloide

Presentación

María del Mar Tormo Díaz es médico facultativo especialista en hematología y profesora asociada de la Universidad de Valencia. Forma parte del Instituto de Investigación Sanitaria INCLIVA de Valencia, desde su constitución y acreditación en el año 2011.

En la actualidad es la responsable del grupo de neoplasias mieloides dentro de la línea de Cáncer del INCLIVA.Su actividad investigadora se ha centrado en el estudio de las leucemias agudas y síndromes mielodisplásicos. En concreto, las líneas de investigación principales desarrolladas en los últimos años han sido en el estudio de polimorfismos genéticos implicados en el desarrollo de leucemias agudas y síndromes mielodisplásicos secundarios a tóxicos, el estudio de nuevos factores pronósticos biológicos en leucemia aguda mieloblástica, el impacto de mutaciones específicas en el tratamiento de los síndromes mielodisplásicos y leucemias agudas mieloides tratadas con agentes hipometilantes.

Posee un profundo conocimiento de la patología mieloide, su biología, expresión clínica, manejo y herramientas terapéuticas disponibles. Forma parte de varios grupos cooperativos nacionales de reconocido prestigio como son el grupo CETLAM (Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplásias), PETHEMA (Programa Español de Tratamientos en Hematología) y GESMD (Grupo español de Síndromes Mielodisplásicos) con una importante actividad científica dentro de ellos.

Investigador
Principal
Dra. Mar Tormo Díaz

maria.mar.tormo@uv.es; tormo_mar@gva.es

Publicaciones
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Ogasawara K, Cavenagh J, Silverman LR, Voso MT, Hellmann A, Tormo M, O’Connor T, Previtali A, Rose S, Garcia-Manero G. Blood Advances. 2022 Apr 12;6(7):2207-2218. doi: 10.1182/bloodadvances.2021005487. PMID: 34972214

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Hellmann A, Taussig DC, Tormo M, Voso MT, Cavenagh J, O’Connor T, Previtali A, Rose S, Silverman LR. Blood advances. 2022 Apr 12;6(7):2219-2229. doi: 10.1182/bloodadvances.2021006138. PMID: 34933333

Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: a series of 372 patients from the PETHEMA AML registry. Hernandez Boluda JC, Martinez Cuadron D, Pereira A, Rodriguez Veiga R, Boluda B, Gil C, Casal-Marini S, Serrano J, Martinez Lopez J, Bergua J, Algarra L, Bernal T, Lopez Lorenzo JL, Colorado M, Lopez A, Tormo M, Sayas MJ, Trigo F, Lopez Pavia M, Perez Simon JA, Lavilla Rubira E, Rodriguez Medina C, Rodriguez Gutierrez JI, Sanz Caballer MA, Montesinos P. Leukemia Research. 2022 Mar 6;115:106821. doi: 10.1016/j.leukres.2022.106821. PMID: 35286939

Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. Piñana JL, Garcia-Sanz R, Martino R, Garcia-Roa M, Martin-Martin GA, Risco-Gálvez I, Tormo M, Martinez-Barranco P, Marcos-Corrales S, Calabuig M, Conesa V, Teruel A, Ruiz-Pérez S, Solano C, Navarro D, Cedillo Á, Sureda A. Blood Advances. 2022 Jan 8;6(3):848-853. doi: 10.1182/bloodadvances.2021006326. PMID: 34905620

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Bataller A, Garrido A, Guijarro F, Onate G, Diaz-Beya M, Arnan M, Tormo M, Vives S, de Llano M, Coll R, Gallardo D, Vall-Llovera F, Escoda L, Garcia-Guinon A, Salamero O, Sampol A, Merchan B, Bargay J, Castano-Diez S, Esteban D, Oliver-Caldes A, Rivero A, Mozas P, Lopez-Guerra M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedeu J, Colomer D, Brunet S, Sierra J, Esteve J. Blood advances. 2022 Feb 22;6(4):1193-1206. doi: 10.1182/bloodadvances.2021005585. PMID: 34911079

Multi-body-site colonization screening cultures for predicting multi-drug resistant Gram-negative and Gram-positive bacteremia in hematological patients. Torres I, Huntley D, Tormo M, Calabuig M, Hernandez-Boluda J, Terol M, Carretero C, de Michelena P, Perez A, Pinana J, Colomina J, Solano C, Navarro D. BMC Infectious Diseases. 2022 Feb 21;22(1):172. doi: 10.1186/s12879-022-07154-3. PMID: 35189833

Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin. Sangerman M, Moreno A, Quintana A, Garcia-Vidal C, Rubio M, Diaz M, Vendranas M, Macias G. Expert Review of Hematology. 2022 Mar 25;1-12. doi: 10.1080/17474086.2022.2054801. PMID: 35332831

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols. Ribera J, Granada I, Morgades M, Gonzalez T, Ciudad J, Such E, Calasanz M, Mercadal S, Coll R, Gonzalez-Campos J, Tormo M, Garcia-Cadenas I, Gil C, Cervera M, Barba P, Costa D, Ayala R, Bermudez A, Orfao A, Ribera J, Programa Tratamiento Hemopatias Ma, Spanish Soc Hematology, SEHH. British Journal of Haematology. 2022 Feb;196(3):670-675. doi: 10.1111/bjh.17844. PMID: 34549416

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Onate G, Bataller A, Garrido A, Hoyos M, Arnan M, Vives S, Coll R, Tormo M, Sampol MA, Escoda L, Salamero O, Garcia A, Bargay J, Aljarilla A, Nomdedeu JF, Esteve J, Sierra J, Pratcorona M. Blood Advances. 2022 Feb 8;6(3):882-890. doi: 10.1182/bloodadvances.2020004136. PMID: 34516636

Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. Pinana J, Vazquez L, Martino R, de la Camara R, Sureda A, Rodriguez-Veiga R, Garrido A, Sierra J, Ribera J, Torrent A, Mateos M, de la Rubia J, Tormo M, Diez-Campelo M, Garcia-Gutierrez V, Alvarez-Larran A, Sancho J, MartinGarcia-Sancho A, Yanez L, Simon J, Barba P, Abrisqueta P, Alvarez-Twose I, Bonanad S, Lecumberri R, Ruiz-Camps I, Navarro D, Hernandez-Rivas J, Cedillo A, Garcia-Sanz R, Bosch F. Leukemia & Lymphoma. 2022 Mar;63(3):538-550. doi: 10.1080/10428194.2021.1992619. PMID: 34668835

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Martinez-Cuadron D, Megias-Vericat JE, Serrano J, Martinez-Sanchez P, Rodriguez-Arboli E, Gil C, Aguiar E, Bergua Burgues JM, Lopez-Lorenzo JL, Bernal T, Espadana A, Colorado M, Rodriguez-Medina C, Lopez-Pavia M, Tormo M, Algarra JL, Amigo ML, Sayas MJ, Labrador J, Rodriguez-Gutierrez JI, Benavente C, Costilla-Barriga L, Garcia-Boyero R, Lavilla E, Vives S, Herrera P, Garcia D, Herraez-Albendea MM, Esteves GV, Gomez-Roncero MI, Cabello A, Bautista G, Balerdi A, Mariz J, Boluda B, Sanz MA, Montesinos P. Blood Advances. 2022 Feb 22;6(4):1278-1295. doi: 10.1182/bloodadvances.2021005335. PMID: 34794172

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience. Labrador J, Saiz-Rodriguez M, de Miguel D, de Laiglesia A, Rodriguez-Medina C, Vidriales M, Perez-Encinas M, Sanchez-Sanchez M, Cuello R, Roldan-Perez A, Vives S, Benzo-Callejo G, Colorado M, Garcia-Fortes M, Sayas M, Olivier C, Recio I, Conde-Royo D, Bienert-Garcia A, Vahi M, Munoz-Garcia C, Seri-Merino C, Tormo M, Vall-Llovera F, Foncillas M, Martinez-Cuadron D, Sanz M, Montesinos P. Cancers. 2022 Mar 29;14(7):1734. doi: 10.3390/cancers14071734. PMID: 35406512

A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. Vives S, Martinez-Cuadron D, Bergua Burgues J, Algarra L, Tormo M, Martinez-Sanchez M, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Lopez-Lorenzo J, Gil C, Vidriales B, Falantes J, Serrano A, Labrador J, Sayas M, Foncillas M, Amador Barciela M, Olave M, Colorado M, Gascon A, Fernandez M, Simiele A, Perez-Encinas M, Rodriguez-Veiga R, Garcia O, Martinez-Lopez J, Barragan E, Paiva B, Sanz M, Montesinos P, PETHEMA Group. Cancer. 2021 Jun 15;127(12):2003-2014. doi: 10.1002/cncr.33403. PMID: 33626197

Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). Genesca E, Morgades M, Gonzalez-Gil C, Fuster-Tormo F, Haferlach C, Meggendorfer M, Montesinos P, Barba P, Gil C, Coll R, Moreno MJ, Martinez-Carballeira D, Garcia-Cadenas I, Vives S, Ribera J, Gonzalez-Campos J, Diaz-Beya M, Mercadal S, Artola MT, Cladera A, Tormo M, Bermudez A, Vall-Llovera F, Martinez-Sanchez P, Amigo ML, Monsalvo S, Novo A, Cervera M, Garcia-Guinon A, Ciudad J, Cervera J, Hernandez-Rivas JM, Granada I, Haferlach T, Orfao A, Sole F, Ribera JM. Leukemia Research. 2021 Jun 8;109:106612. doi: 10.1016/j.leukres.2021.106612. PMID: 34139642

Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia. Ribera J, Morgades M, Ciudad J, Montesinos P, Esteve J, Genesca E, Barba P, Ribera J, Garcia Cadenas I, Moreno M, Martinez-Carballeira D, Torrent A, Martinez-Sanchez P, Monsalvo S, Gil C, Tormo M, Artola M, Cervera M, Gonzalez-Campos J, Rodriguez-Medina C, Bermudez A, Novo A, Soria B, Coll R, Amigo M, Lopez A, Fernandez Martin R, Serrano J, Mercadal S, Cladera A, Gimenez-Conca A, Penarrubia M, Abella E, Vall-Llovera F, Hernandez-Rivas J, Garcia A, Bergua Burgues J, de Rueda B, Sanchez-Sanchez M, Serrano A, Calbacho M, Alonso Vence N, Mendez-Sanchez J, Garcia-Boyero R, Olivares M, Barrena S, Zamora L, Granada I, Lhermitte L, Feliu E, Orfao A. Blood. 2021 Apr 8;137(14):1879-1894. doi: 10.1182/blood.2020007311. PMID: 33150388

Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival. Cabezon M, Malinverni R, Bargay J, Xicoy B, Marce S, Garrido A, Tormo M, Arenillas L, Coll R, Borras J, Jimenez M, Hoyos M, Valcarcel D, Escoda L, Vall-Llovera F, Garcia A, Font L, Ramila E, Buschbeck M, Zamora L, CETLAM Grp. Clinical Epigenetics. 2021 Jan 14;13(1):9. doi: 10.1186/s13148-021-01002-y. PMID: 33446256

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. Boluda B, Martinez-Cuadron D, Algarra L, Cano I, Sayas M, Acuna-Cruz E, Blanco A, Marco-Ayala J, DeLapuerta R, Diaz-Gonzalez A, Tormo M, Rodriguez-Veiga R, Garcia R, Pinana J, Lopez-Pavia M, Barragan E, Amigo M, Sargas C, Lopez A, Solana-Altabella A, Gil C, Megias-Vericat J, Sanz M, Montesinos P. Leukemia & Lymphoma. 2021 Nov;62(11):2727-2736. doi: 10.1080/10428194.2021.1938031. PMID: 34121593

Evolving treatment patterns and outcomes in older patients (?60 years) with AML: changing everything to change nothing?. Martinez-Cuadron D, Serrano J, Gil C, Tormo M, Martinez-Sanchez P, Perez-Simon J, Garcia-Boyero R, Rodriguez-Medina C, Lopez-Pavia M, Benavente C, Bergua J, Lavilla-Rubira E, Amigo M, Herrera P, Alonso-Dominguez J, Bernal T, Colorado M, Sayas M, Algarra L, Vidriales M, Rodriguez-Macias G, Vives S, Perez-Encinas M, Lopez A, Noriega V, Garcia-Fortes M, Ramos F, Rodriguez-Gutierrez J, Costilla-Barriga L, Labrador J, Boluda B, Rodriguez-Veiga R, Martinez-Lopez J, Sanz M, Montesinos P. Leukemia. 2021 Jun;35(6):1571-1585. doi: 10.1038/s41375-020-01058-4. PMID: 33077867

Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. Simoes C, Paiva B, Martinez-Cuadron D, Bergua J, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez J, Vidriales M, Labrador J, Falantes J, Sayas M, Ayala R, Martinez-Lopez J, Villar S, Calasanz M, Prosper F, San-Miguel J, Sanz M, Montesinos P. Blood Advances. 2021 Feb 9;5(3):760-770. doi: 10.1182/bloodadvances.2020003195. PMID: 33560390

Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. Martin I, Villamon E, Abellan R, Calasanz M, Irigoyen A, Sanz G, Such E, Mora E, Gutierrez M, Collado R, Garcia-Serra R, Vara M, Blanco M, Oiartzabal I, Alvarez S, Bernal T, Granada I, Xicoy B, Jerez A, Calabuig M, Diez R, Gil A, Diez-Campelo M, Solano C, Tormo M, Spanish Grp Myelodysplastic Syn. British Journal of Haematology. 2021 Aug;194(4):708-717. doi: 10.1111/bjh.17675. PMID: 34296432

Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML Project. Sargas C, Ayala R, Chillon M, Larrayoz M, Carrillo-Cruz E, Bilbao C, Yebenes-Ramirez M, Llop M, Rapado I, Garcia-Sanz R, Vazquez I, Soria E, Florido-Ortega Y, Janusz K, Botella C, Serrano J, Martinez-Cuadron D, Bergua J, Amigo M, Martinez-Sanchez P, Tormo Diaz M, Bernal T, Herrera-Puente P, Garcia R, Algarra L, Sayas M, Costilla-Barriga L, Perez-Santolalla E, Marchante I, Lavilla-Rubira E, Noriega V, Alonso-Dominguez J, Sanz M, Sanchez-Garcia J, Gomez-Casares M, Perez-Simon J, Calasanz M, Gonzalez-Diaz M, Martinez-Lopez J, Barragan E, Montesinos P. Haematologica. 2021 Dec 1;106(12):3079-3089. doi: 10.3324/haematol.2020.263806. PMID: 33179471

Outcome of older (>= 70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study (vol 34, pg 2333, 2020). Kayser S, Rahme R, Martinez-Cuadron D, Ghiaur G, Thomas X, Sobas M, Guerci-Bresler A, Garrido A, Pigneux A, Gil C, Raffoux E, Tormo M, Vey N, de la Serna J, Salamero O, Lengfelder E, Levis MJ, Fenaux P, Sanz MA, Platzbecker U, Schlenk RF, Ades L, Montesinos P. Leukemia. 2021 Dec;35(12):3631. doi: 10.1038/s41375-021-01358-3. PMID: 34785795

Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. Ribera J, Morgades M, Genesca E, Chapchap E, Montesinos P, Acuna-Cruz E, Gil C, Garcia-Cadenas I, Barba P, Gonzalez-Campos J, de Llano M, Torrent A, Ribera J, Granada I, Bernal T, Diaz-Beya M, Amigo M, Coll R, Tormo M, Vall-llovera F, Gomez-Centurion I, Sanchez-Sanchez M, Soria B, Cladera A, Artola M, Garcia-Guinon A, Gimenez-Conca A, Amador M, Martinez-Sanchez P, Algarra J, Vidal M, Alonso N, Maluquer C, Llorente L, Garcia-Boyero R, Ciudad J, Feliu E, Orfao A, PETHEMA Grp. Hematological Oncology. 2021 Oct;39(4):529-538. doi: 10.1002/hon.2910. PMID: 34405901

The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the PETHEMA-FLUGAZA phase 3 clinical trial. Ayala R, Rapado I, Onecha E, Martinez-Cuadron D, Carreno-Tarragona G, Bergua J, Vives S, Algarra J, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lorenzo J, Vidriales M, Labrador J, Falantes J, Sayas M, Paiva B, Barragan E, Prosper F, Sanz M, Martinez-Lopez J, Montesinos P, PETHEMA Cooperative Study Grp. Cancers. 2021 May 18;13(10):2458. doi: 10.3390/cancers13102458. PMID: 34070172

A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial. Ribera J, Morgades M, Montesinos P, Tormo Diaz M, Martinez-Carballeira D, Gonzalez-Campos J, Gil C, Barba P, Garcia-Boyero R, Coll R, Pedreno M, Ribera J, Mercadal S, Vives S, Novo A, Genesca E, Hernandez-Rivas J, Bergua J, Amigo M, Vall-Llovera F, Martinez-Sanchez P, Calbacho M, Garcia-Cadenas I, Garcia-Guinon A, Sanchez-Sanchez M, Cervera M, Feliu E, Orfao A, Spanish Soc Hematology. Cancer Medicine. 2020 Apr;9(7):2317-2329. doi: 10.1002/cam4.2814. PMID: 32022463

Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. Bataller A, Onate G, Diaz-Beya M, Guijarro F, Garrido A, Vives S, Tormo Diaz M, Arnan M, Salamero O, Sampol A, Coll R, Vall-Llovera F, Oliver-Caldes A, Lopez-Guerra M, Pratcorona M, Zamora L, Villamón Ribate E, Rou G, Blanco A, Nomdedeu J, Colomer D, Brunet S, Sierra J, Esteve J, Grp Cooperativo Estudio Tratamient. British Journal of Haematology. 2020 Oct;191(1):52-61. doi: 10.1111/bjh.16857. PMID: 32510599

Application of a digital PCR method for WT1 to myeloid neoplasms in CR and deep ELN WT1 molecular response (< 10 copies). Bussaglia E, Pratcorona M, Carricondo M, Sansegundo L, Rubio M, Monter A, Brell A, Badell I, Esteve J, Arnan M, Talarn C, Tormo Diaz M, Garcia A, Vall-Llovera F, Ortin X, Pedro C, Bargay J, Brunet S, Sierra J, Nomdedeu J. Annals of Hematology. 2020 Apr;99(4):765-772. doi: 10.1007/s00277-020-03910-0. PMID: 32062741

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. Sobas M, Rodriguez-Veiga R, Vellenga E, Paluszewska M, De la Serna J, Garcia-Alvarez F, Gil C, Brunet S, Bergua J, Gonzalez-Campos J, Ribera J, Tormo Diaz M, Gonzalez M, Fernandez I, Benavente C, Gonzalez-Sanmiguel J, Esteve J, Perez-Encinas M, Salamero O, Manso F, Lowenberg B, Sanzs M, Montesinos P, PETHEMA H. European Journal of Haematology. 2020 Mar;104(3):162-169. doi: 10.1111/ejh.13346. PMID: 31724208

Clinical significance of Pneumocystis jirovecii DNA detection by real-time PCR in hematological patient respiratory specimens. Luis Pinana J, Albert Vicent E, Dolores Gomez M, Perez Martinez A, Hernandez Boluda J, Montoro J, Salavert M, Maria Gonzalez E, Tormo Diaz M, Gimenez Quiles E, Villalba M, Balaguer-Rosello A, Hernani Morales R, Bueno Ferrando F, Borras Salvador R, Sanz J, Solano Vercet C, Navarro Ortega D. The Journal of infection. 2020 May;80(5):578-606. doi: 10.1016/j.jinf.2020.01.001. PMID: 31926954

Corrigendum to «Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study» [Leuk. Res. 92 (March) (2020) 106352. Rodríguez-Medina C, Martínez-Cuadrón D, Cano I, Gil C, Tormo Diaz M, Del Pilar Martínez-Sánchez M, Del Castillo T, Serrano-López J, Benavente C, Herrera-Puente P, García-Boyero R, Lavilla-Rubira E, Luz Amigo M, Sayas-Lloris M, Bergua-Burgues J, Pérez-Simón J, Rodríguez G, Espadana A, Vidriales-Vicente B, Fernández R, López-Lorenzo J, López M, García-Fortes M, Gómez J, Colorado-Araujo M, Sossa-Melo C, Aguilar E, Montesinos P. Leukemia Research. 2020 Sep;96:106388. doi: 10.1016/j.leukres.2020.106388. PMID: 32680618

Early adjustment of empirical antibiotic therapy of bloodstream infections on the basis of direct identification of bacteria by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and Gram staining results. Torres Fink I, Pinto Plá C, Oltra Sempere R, Pascual Martín T, Carbonell Monleon N, Colomina Rodríguez F, Tormo Diaz M, Albert Vicent E, Aguilar Aguilar G, Solano Vercet C, Navarro Ortega D. Journal of Infection and Chemotherapy. 2020 Sep;26(9):963-969. doi: 10.1016/j.jiac.2020.04.019. PMID: 32386929

Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium. Sanchez-Maldonado J, Campa D, Springer J, Badiola J, Niazi Y, Moniz-Diez A, Hernandez-Mohedo F, Gonzalez-Sierra P, Ter Horst R, Macauda A, Brezina S, Cunha C, Lackner M, Lopez-Nevot M, Fianchi L, Pagano L, Lopez-Fernandez E, Potenza L, Luppi M, Moratalla L, Rodriguez-Sevilla J, Fonseca J, Tormo Diaz M, Solano Vercet C, Clavero E, Romero A, Li Y, Lass-Florl C, Einsele H, Vazquez L, Loeffler J, Hemminki K, Carvalho A, Netea M, Gsur A, Dumontet C, Canzian F, Forsti A, Jurado M, Sainz J. Blood Cancer Journal. 2020 Jul 16;10(7):75. doi: 10.1038/s41408-020-00341-y. PMID: 32678078

Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. Martin Gonzalez I, Navarro Cubells B, Serrano Alcalá A, Villamón Ribate E, Calabuig Muñoz M, Solano Vercet C, Chaves Martínez F, Yague N, Orts M, Amat Martínez P, Fuentes Trillo A, Seda García E, García García F, Hernandez Boluda J, Tormo Diaz M. Annals of Hematology. 2020 Mar;99(3):527-537. doi: 10.1007/s00277-020-03932-8. PMID: 31989250

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Stahl M, Shallis R, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt V, Sekeres M, Fathi A, Konig H, Luger S, Khan I, Roboz G, Cluzeau T, Martinez-Cuadron D, Raffoux E, Germing U, Umakanthan J, Mukherjee S, Brunner A, Miller A, McMahon C, Ritchie E, Rodriguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo Diaz M, Acuna-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev N, Bewersdorf J, Gore S, Zeidan A. Leukemia. 2020 Dec;34(12):3149-3160. doi: 10.1038/s41375-020-0783-3. PMID: 32132655

Outcome of older (>= 70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. Kayser S, Rahme R, Martinez-Cuadron D, Ghiaur G, Thomas X, Sobas M, Guerci-Bresler A, Garrido A, Pigneux A, Gil C, Raffoux E, Tormo Diaz M, Vey N, de la Serna J, Salamero O, Lengfelder E, Levis M, Fenaux P, Sanz M, Platzbecker U, Schlenk R, Ades L, Montesinos P. Leukemia. 2020 Sep;34(9):2333-2341. doi: 10.1038/s41375-020-0758-4.PMID: 32076120

Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Shallis R, Stahl M, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt V, Sekeres M, Fathi A, Konig H, Luger S, Khan I, Roboz G, Cluzeau T, Martinez-Cuadron D, Raffoux E, Germing U, Umakanthan J, Mukhereje S, Brunner A, Miller A, McMahon C, Ritchie E, Rodriguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo Diaz M, Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev N, Bewersdorf J, Gore S, Zeidan A. Leukemia & Lymphoma. 2020 May;61(5):1220-1225. doi: 10.1080/10428194.2020.1728753. PMID: 32100599

Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study. Rodriguez-Medina C, Martinez-Cuadron D, Cano I, Gil C, Tormo Diaz M, Del Pilar Martinez-Sanchez M, Del Castillo T, Serrano-Lopez J, Benavente C, Herrera-Puente P, Garcia-Boyero R, Lavilla-Rubira E, Amigo M, Sayas-Lloris M, Bergua-Burgues J, Perez-Simon J, Rodriguez G, Espadana A, Vidriales-Vicente B, Fernandez R, Lopez-Lorenzo J, Lopez M, Garcia-Fortes M, Labrador Gomez J, Colorado-Araujo M, Sossa-Melo C, Aguilar E, Montesinos Fernandez P. Leukemia Research. 2020 Mar 23;92:106352. doi: 10.1016/j.leukres.2020.106352. PMID: 32240863

Scute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). study of 61 patients treated with intensive protocols.. Sitges M, Boluda B, Garrido A, Morgades M, Granada I, Barragan E, Arnan M, Serrano J, Tormo Diaz M, Miguel Bergua J, Colorado M, Salamero O, Esteve J, Benavente C, Perez-Encinas M, Coll R, Marti-Tutusaus J, Brunet S, Sierra J, Angel Sanz M, Montesinos P, Ribera J, Vives S, PETHEMA C. European Journal of Haematology. 2020 Aug;105(2):138-147. doi: 10.1111/ejh.13417. PMID: 32243655

Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy. Ribera J, Garcia O, Chapchap E, Gil C, Gonzalez-Campos J, Barba P, Amigo M, Moreno M, Lavilla E, Alonso N, Bergua J, Tormo Diaz M, Ribera J, Sierra M, Martinez-Carballeira D, Mercadal S, Hernandez-Rivas J, Vall-Llovera F, Genesca E, Cladera A, Novo A, Abella E, Garcia-Cadenas I, Monteserin C, Bermudez A, Piernas S, Montesinos P, Lopez J, Garcia-Guinon A, Serrano A, Martinez M, Olivares M, Lopez A, Serrano J, PETHEMA Group S. Clinical Lymphoma, Myeloma & Leukemia. 2020 Aug;20(8):e513-e522. doi: 10.1016/j.clml.2020.03.011. PMID: 32336676

UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy. Diaz-Santa J, Rodriguez-Romanos R, Osca G, Pratcorona M, Garrido A, Coll R, Moret C, Escoda L, TORMO DIAZ M, Heras I, Arnan M, Vives S, Salamero O, Lloveras N, Bargay J, Sampol A, Cruz D, Garcia A, Quinones T, Esteve J, Sierra J, Gallardo D, on the behalf of CETLAM Group. Leukemia. 2020 Nov;34(11):2925-2933. doi: 10.1038/s41375-020-0784-2. PMID: 32152464

Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia. Genesca E, Morgades M, Montesinos P, Barba P, Gil C, Guardia R, Moreno M, Martinez-Carballeira D, Garcia-Cadenas I, Vives S, Ribera J, Gonzalez-Campos J, Gonzalez-Gil C, Zamora L, Ramirez J, Diaz-Beya M, Mercadal S, Artola M, Cladera A, Tormo Diaz M, Bermudez A, Vall-Llovera F, Martinez P, Amigo M, Monsalvo S, Novo A, Cervera M, Garcia-Guinon A, Junca J, Ciudad J, Orfao A, Ribera J. Haematologica. 2020 Jun;105(6):e294-e297. doi: 10.3324/haematol.2019.225078. PMID: 31537688

+ Información
Título: Rol del complejo RUNX1-CBF-Β/HIPK2/p300/p53 en la evolución leucémica de las neoplasias mieloproliferativas crónicas
Doctorando: Lozano Asencio, Carlos Alberto
Director: Hernández Boluda, Juan Carlos; Climent Bataller, Joan
Fecha: 14/02/2020
Universidad: Universitat de València

Título: Caracterización molecular de la anemia refractaria con sideroblastos en anillo mediante un panel de secuenciación de segunda generación
Doctorando: Martín Castillo, Iván
Director: Sanz Alonso, Miguel Ángel; Such Taboada, Esperanza; Cervera Zamora, Jose Vicente
Fecha: 06/02/2020
Universidad: Universitat de València

Título: Análisis de la relación coste-efectividad del tratamiento con azacitidina en pacientes con síndrome mielodisplásico en el hospital clínico universitario de valencia
Doctorando: Torrecilla Junyent, Teresa
Director: Alós Almiñana, Manuel; Tormo Díaz, María del Mar; Cortijo Gimeno, Julio
Fecha: 12/06/2019
Universidad: Universitat de València